| Abstrakt: |
A study conducted by researchers from Mayo Clinic in Jacksonville, Florida, examined the efficacy of CD19-directed therapies in patients with relapsed or refractory large B-cell lymphoma (LBCL) who had previously received CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included 53 patients with a median follow-up of 56 weeks. The overall response rate and complete response rates were 27% and 10%, respectively, with a median duration of response of 13.3 weeks. The researchers concluded that the currently approved CD19-directed therapies showed limited clinical activity and duration of responses in treating relapsed or refractory LBCL after CD19-CAR-T therapy. [Extracted from the article] |
